Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. British trial shows clear effects of treatment, especially blood pressure reduction.

× No keyword cloud information.

16 in total

1. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.

Authors:
Journal: BMJ Date: 1998-09-12

2. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.

Authors:
Journal: BMJ Date: 1998-09-12

3. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

Authors:
Journal: BMJ Date: 1998-09-12

Review 4. Cardiovascular risk continuum: implications of insulin resistance and diabetes.

Authors: W A Hsueh; R E Law
Journal: Am J Med Date: 1998-07-06 Impact factor: 4.965

5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors: D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal: N Engl J Med Date: 1993-09-30 Impact factor: 91.245

6. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors:
Journal: Lancet Date: 1998-09-12 Impact factor: 79.321

7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors:
Journal: Lancet Date: 1998-09-12 Impact factor: 79.321

8. The quest for normoglycaemia: a historical perspective.

Authors: R B Tattersall
Journal: Diabet Med Date: 1994 Aug-Sep Impact factor: 4.359

9. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy.

Authors: C E Mogensen
Journal: Br Med J (Clin Res Ed) Date: 1982-09-11

Review 10. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

Authors: R Collins; R Peto; S MacMahon; P Hebert; N H Fiebach; K A Eberlein; J Godwin; N Qizilbash; J O Taylor; C H Hennekens
Journal: Lancet Date: 1990-04-07 Impact factor: 79.321

18 in total

Review 1. Is normotension good enough for the patient with type 2 diabetes?

Authors: E Ritz; M Schömig
Journal: Curr Hypertens Rep Date: 1999-10 Impact factor: 5.369

2. Diabetic nephropathy: evidence for renoprotection and practice.

Authors: C E Mogensen
Journal: Heart Date: 2000-09 Impact factor: 5.994

3. The angiotensin-I converting enzyme gene I/D variation contributes to end-stage renal disease risk in Chinese patients with type 2 diabetes receiving hemodialysis.

Authors: Ming Lu; Jianzhong Zhang; Ming Li; Xiaoxu Ge; Xu Dai; Jiao Zhao; Mingzhou Fu; Tao Wang; Xiyao Fang; Can Li; Rong Zhang; Weijing Zhao; Taishan Zheng; Feng Wang; Ming Yu; Tao Lei; Niansong Wang; Yuqian Bao; Limei Liu; Yanjun Liu; Weiping Jia
Journal: Mol Cell Biochem Date: 2016-09-16 Impact factor: 3.396

4. Hyperglycemia and renin-dependent hypertension synergize to model diabetic nephropathy.

Authors: Bryan R Conway; Jillian Rennie; Matthew A Bailey; Donald R Dunbar; Jonathan R Manning; Christopher O Bellamy; Jeremy Hughes; John J Mullins
Journal: J Am Soc Nephrol Date: 2011-12-22 Impact factor: 10.121

5. Characteristics of end stage renal disease diabetic patients in two countries with different socioeconomic conditions.

Authors: Emmanuel I Agaba; Oladipo Adeniyi; Karen S Servilla; Dorothy J Vanderjagt; Robert H Glew; Antonios H Tzamaloukas
Journal: Int Urol Nephrol Date: 2004 Impact factor: 2.370

Review 6. Antihypertensive drugs and diabetic nephropathy.

Authors: P S Mehler; R W Schrier
Journal: Curr Hypertens Rep Date: 1999 Apr-May Impact factor: 5.369

7. Arg913Gln of SLC12A3 gene promotes development and progression of end-stage renal disease in Chinese type 2 diabetes mellitus.

Authors: Rong Zhang; Langen Zhuang; Ming Li; Juan Zhang; Weijing Zhao; Xiaoxu Ge; Yating Chen; Feng Wang; Niansong Wang; Yuqian Bao; Limei Liu; Yanjun Liu; Weiping Jia
Journal: Mol Cell Biochem Date: 2017-07-25 Impact factor: 3.396

Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. British trial shows clear effects of treatment, especially blood pressure reduction.

1. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.

2. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.

3. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

Review 4. Cardiovascular risk continuum: implications of insulin resistance and diabetes.

5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

6. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

8. The quest for normoglycaemia: a historical perspective.

9. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy.

Review 10. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

Review 1. Is normotension good enough for the patient with type 2 diabetes?

2. Diabetic nephropathy: evidence for renoprotection and practice.

3. The angiotensin-I converting enzyme gene I/D variation contributes to end-stage renal disease risk in Chinese patients with type 2 diabetes receiving hemodialysis.

4. Hyperglycemia and renin-dependent hypertension synergize to model diabetic nephropathy.

5. Characteristics of end stage renal disease diabetic patients in two countries with different socioeconomic conditions.

Review 6. Antihypertensive drugs and diabetic nephropathy.

7. Arg913Gln of SLC12A3 gene promotes development and progression of end-stage renal disease in Chinese type 2 diabetes mellitus.

8. Participating in the United Kingdom Prospective Diabetes Study (UKPDS): a qualitative study of patients' experiences.

9. Standard and Novel Treatment Options for Metabolic Syndrome and Diabetes Mellitus.

10. Arterial hypertension in diabetes mellitus: from theory to clinical practice.